Overview

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2022-12-13

Target enrollment:

Participant gender:

Summary

Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by a Response Adjudication Committee (RAC).

Phase:

Phase 3

Details

Lead Sponsor:

The Lymphoma Academic Research Organisation

Treatments:

Romidepsin